|
Jury still out on use of IVIG for Stevens-Johnson: calls for a randomized controlled trial.(News)(intravenous immunoglobulin )
Publication: Skin & Allergy News Publication Date: 01-DEC-03 Author: Jancin, Bruce
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2003 International Medical News Group
BARCELONA, SPAIN -- It's far too premature to crown intravenous immunoglobulin as the new standard of care in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis, Dr. Robert S. Stern reported at the 12th Congress of the European Academy of Dermatology and Venereology.
Some physicians are eager to declare intravenous immunoglobulin (IVIG) the magic bullet for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). But on balance, the evidence against IVIG having a therapeutic effect in this rare, potentially fatal spectrum of drug reactions is...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Skin & Allergy News |
Receptor on macrophages key to TNF regulation: brain's role in inflamm...
December 01, 2003
|
Beware eruptive xanthomas with olanzapine Tx: tied to hypertriglycerid...
December 01, 2003
|
Apoptotic markers aberrant in keloids but not in normal scars: key rol...
December 01, 2003
|
Bug tales.(Under My Skin)
December 01, 2003
|
The side effects of TV makeovers.(Guest Editorial)(ethics of reality t...
December 01, 2003
|
|
| Find companies classified under Pharmaceutical preparations |
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
